Fina Biosolutions LLC

11/10/2020

Fina Biosolutions announces its proprietary method of producing CRM197 will be used to develop low cost, affordable vaccines for children and adults in developing nations

Fina Biosolutions Announces European Patent for Conjugate Vaccine Development and Proprietary Method of Producing CRM197.

09/17/2019

Fina Biosolutions LLC of Rockville, MD has signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine. The Kunming Institute is one of China’s premier virology institute.…

06/18/2019

Fina Biosolutions had a very successful BIO week. Not only did we get to chat with potential and existing customer companies but had had the opportunity to make new friends and learn about some terrific technology. Maryland had a large, well-located pavilion and FinaBio was proud to be a participating company, sharing a stand with LabOwl. ,

05/30/2019

We will be at BIO Philadelphia as part of the Maryland Pavilion!

12/03/2018

Watch Maryland Tech Council interview our founder!

Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving us a behind the scenes tour of their lab, located…

11/15/2018

ANNOUNCING: Fina Biosolutions licenses CRM197 vaccine component to PATH to develop important vaccines for use in low-income countries.

Fina Biosolutions licenses CRM197 vaccine component to PATH for use in low-income countries November 15, 2018 06:00 AM Eastern Standard Time ROCKVILLE, Md. – Fina Biosolutions LLC announced today it has reached agreement with PATH, a global organization focused on solving some of the world’s…

09/27/2018

Fina Biosolutions will be presenting on our conjugate vaccine carrier protein program at the International Society of Vaccines meeting in Atlanta, Oct 28-30 and Vaccine R&D meeting in Baltimore, Nov 13-15.

04/02/2018

FinaBio will be at the World Vaccine Congress, Washington DC April 3-5. We will have 2 poster presentations on our recombinant CRM197 conjugate vaccine carrier protein. One poster will be a biophysical characterization of our CRM197 and the other will be on the immunology of conjugates made with it. They will be added to the other CRM197 posters available on our website.

02/08/2018

"Value pricing is based on money saved and is often used to justify high prices for drugs. A better model for vaccines that every child on the planet should get is "cost plus", where the price is set to give the manufacturer a fair but not outrageous profit."

On February 1, 2018, Andrew Lees spoke at the Keystone meeting, Emerging Technologies in Vaccine Discovery and Development, held in Banff, Alberta, Canada. He chaired the session, “New Tools in Vaccine Manufacturing and Product Analytics”. During the session, Dr. Lees…

10/01/2016

I recently presented a seminar at the Uniformed Services University Dept of Medicine on Affordable Conjugate Vaccines. I discussed Fina Biosolutions efforts in developing "EcoCRM"an affordable version of the vaccine carrier protein CRM197 (https://en.wikipedia.org/wiki/CRM197). There was a display in the lobby of the University Administration building that featured patents and products developed by University faculty. One of the panes featured the GSK conjugate vaccines that use the CDAP chemistry I developed (see photo).